A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
Unknown status
Beijing Cancer Hospital
Phase 1
SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this
study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in
Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will
be also investigated in this study.
A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
Unknown status
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
SHR6390 is a small molecular,oral potent, selective CDK4/6 inhibitor. The purpose of this
study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in
Chinese advanced melanoma patients by using a "3+3" dose escalation.Preliminary efficacy will
be also investigated in this study.
A Study of SHR6390 in Advanced Solid Tumor Patients
Unknown status
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this
study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in
Chinese advanced solid tumor patients by using a "3+3" dose escalation.Preliminary efficacy
will be also investigated in this study.
Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
Unknown status
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
The aim of the study is to assess the safety and tolerability of SHR6390 combined with
pyrotinib in the patients with Her-2 positive advanced gastric cancer.
Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
Unknown status
Peking University
Phase 1
The aim of the study is to assess the safety and tolerability of SHR6390 combined with
pyrotinib in the patients with Her-2 positive advanced gastric cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
